Rasagiline
Rasagilina
- Date
- c. 1994 · confidence low
- Place
- Haifa, Israel
- Credited to
- Moussa B. H. Youdim
- Field
- Life & health
What it is
A selective monoamine oxidase B inhibitor drug used to treat Parkinson's disease, either as monotherapy in early stages or as adjunct therapy in advanced cases.
Developed by pharmacologist Moussa Youdim at the Technion in Haifa; it differs pharmacologically from selegiline by not producing amphetamine-like metabolites.
What it led to
- New Parkinson's treatment options with fewer side effects
- Approval in the European Union (2005) and the United States (2006)
Built on
- Selegiline (MAO-B inhibitor)